- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Prithviraj Bose on Treating Progression in Myelofibrosis
Prithviraj Bose, MD, of MD Anderson Cancer Center discusses treatment options for patients progressing with myelofibrosis.
Prithviraj Bose, MD, of MD Anderson Cancer Center discusses treatment options for patients progressing with myelofibrosis.
How do you treat progression in myelofibrosis?
So, it’s a lot of things, and currently there is not a whole lot that is available for these patients. Ruxolitinib is our standard first-line drug for most patients with myelofibrosis and progression to me generally mean progression on ruxolitinib. So, we just had the FDA approve fedratinib, so that is a new option now, which certainly would be a valid option in a good number of patients who progress on ruxolitinib. There is data from the JAKARTA-2 study supporting fedratinib’s use in the post-ruxolitinib setting.
But where it gets interesting is that you have to look at the definitions used in various trials that have studied agents in the post-ruxolitinib setting. So, JAKARTA-2, for example, originally had a fairly loose definition and then the data were reanalyzed using a stringent definition, which I hope is becoming more of a consensus because the recent trial of pacritinib, PAC203—pacritinib is another JAK 2 inhibitor—used the same definitions as they used in the revised analysis of JAKARTA-2. So, hopefully some sort of a consensus is emerging in the field.
And what was interesting was when they used the revised definition, the response rates dramatically changed. They originally reported spleen response rate was 55% and with the new definition it was 30%. Symptom response rate was virtually identical, 26% and 27% on the original and the reanalysis.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
